According to the guidelines by the European Group of Tumor Markers, HE4 measurements, either alone in combinations with CA125 in ROMA, should be considered for differential diagnosis of pelvic masses, especially in premenopausal patients (40). This evidence concerns the gene WFDC2 and neoplasm.